<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Forum Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Open Forum Infect Dis</journal-id><journal-id journal-id-type="publisher-id">ofid</journal-id><journal-title-group><journal-title>Open Forum Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">2328-8957</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">5630729</article-id><article-id pub-id-type="doi">10.1093/ofid/ofx163.963</article-id><article-id pub-id-type="publisher-id">ofx163.963</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts</subject><subj-group subj-group-type="category-toc-heading"><subject>Poster Abstract</subject></subj-group></subj-group></article-categories><title-group><article-title>Successful Response to Microbiota-Based Drug RBX2660 in Patients with Recurrent <italic>Clostridium Difficile</italic> Infection is Associated with More Pronounced Alterations in Microbiome Profile</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Khanna</surname><given-names>Sahil</given-names></name><degrees>MBBS, MS</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Blount</surname><given-names>Ken</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Jones</surname><given-names>Courtney</given-names></name><degrees>BS</degrees><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Shannon</surname><given-names>Bill</given-names></name><degrees>PhD, MBA</degrees><xref ref-type="aff" rid="AF0004">4</xref></contrib><contrib contrib-type="author"><name><surname>Carter</surname><given-names>Sharina</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0004">4</xref></contrib></contrib-group><aff id="AF0001">
<label>1</label>
<institution>Gastroenterology and Hepatology, Mayo Clinic</institution>, <addr-line>Rochester, Minnesota</addr-line></aff><aff id="AF0002">
<label>2</label>
<institution>Rebiotix</institution>, <addr-line>Roseville, Minnesota</addr-line></aff><aff id="AF0003">
<label>3</label>
<institution>Rebiotix Inc.</institution>, <addr-line>Roseville, Minnesota</addr-line></aff><aff id="AF0004">
<label>4</label>
<institution>BioRankings LLC</institution>, <addr-line>St. Louis, Missouri</addr-line></aff><author-notes><fn id="fn-0001"><p>
<bold>Session:</bold> 148. C. difficile: From the Bench to Bedside</p><p>
<italic>Friday, October 6, 2017: 12:30 PM</italic>
</p></fn></author-notes><pub-date pub-type="collection"><season>Fall</season><year>2017</year></pub-date><pub-date pub-type="epub" iso-8601-date="2017-10-04"><day>04</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>04</day><month>10</month><year>2017</year></pub-date><volume>4</volume><issue>Suppl 1</issue><issue-title>ID Week 2017 Abstracts</issue-title><fpage>S387</fpage><lpage>S387</lpage><permissions><copyright-statement>© The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</copyright-statement><copyright-year>2017</copyright-year><license license-type="cc-by-nc-nd" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri xlink:href="ofx163.963.pdf"></self-uri><abstract><title><offsets xml_i="4280" xml_f="4288" txt_i="11" txt_f="19">Abstract</offsets></title><sec id="s1"><title><offsets xml_i="4316" xml_f="4326" txt_i="20" txt_f="30">Background</offsets></title><p><offsets xml_i="4337" xml_f="4347" txt_i="31" txt_f="41">Recurrent </offsets><italic><offsets xml_i="4355" xml_f="4376" txt_i="41" txt_f="62">Clostridium difficile</offsets></italic><offsets xml_i="4385" xml_f="4809" txt_i="62" txt_f="486"> infections (rCDI) are associated with decreased diversity and altered intestinal microbiome compared with healthy patients. RBX2660, a standardized microbiota-based drug, is designed to restore microbiome diversity and composition in patients’. The effect of RBX2660 on rCDI patient microbiomes was evaluated by comparing pre- and post-treatment samples from PUNCH CD 2—a randomized, double-blind, placebo-controlled study.</offsets></p></sec><sec id="s2"><title><offsets xml_i="4839" xml_f="4846" txt_i="488" txt_f="495">Methods</offsets></title><p><offsets xml_i="4857" xml_f="5288" txt_i="496" txt_f="927">rCDIsubjects were randomized to receive blinded treatments of 2 doses of RBX2660 (Group A), 2 doses of placebo (Group B), or 1 dose each of RBX2660 and placebo (Group C), by enema 7 days apart. Subjects submitted stool samples at baseline, day 7, 30, and 60 after treatment. Stool samples from responders to RBX2660 treatment per protocol defined as the absence of CDI for 8 weeks after treatment were compared with non-responders.</offsets></p><p><offsets xml_i="5295" xml_f="5748" txt_i="928" txt_f="1381">Relative taxonomic abundances at the class level were determined using 16s rRNA sequencing analysis for 94 stool samples from 45 patients in Groups A and C. Relative abundance data were grouped longitudinally using Bray-Curtis dissimilarity index. Analyses were performed based on the Dirichlet-Multinomial distribution to compare group mean relative taxonomic abundances; Simpson and Shannon diversity indices were compared among groups longitudinally.</offsets></p></sec><sec id="s3"><title><offsets xml_i="5778" xml_f="5785" txt_i="1383" txt_f="1390">Results</offsets></title><p><offsets xml_i="5796" xml_f="6323" txt_i="1391" txt_f="1918">Baseline patient microbiomes were similar across response groups. RBX2660 treatment shifted the relative microbiome densities with taxa-specific increase in Bacteroidia, Clostridia, and decrease in Gamma-proteobacteria abundance. A larger shift from baseline microbiome was seen in responders to RBX2600 compared with non-responders (Figure 1). Microbiome changes in responders were durable to 60 days. RBX2660 treatment increased Shannon and Simpson diversity at 7 days post-treatment in responders but not in non-responders (</offsets><italic><offsets xml_i="6331" xml_f="6337" txt_i="1918" txt_f="1921">P &lt;</offsets></italic><offsets xml_i="6346" xml_f="6353" txt_i="1921" txt_f="1928"> 0.05).</offsets></p></sec><sec id="s4"><title><offsets xml_i="6383" xml_f="6393" txt_i="1930" txt_f="1940">Conclusion</offsets></title><p><offsets xml_i="6404" xml_f="6534" txt_i="1941" txt_f="2071">RBX2660 treatment shifts patient intestinal microbiomes with greater alterations seen in those with a successful clinical outcome.</offsets></p><p><offsets xml_i="6541" xml_f="6580" txt_i="2072" txt_f="2111">Funded by Rebiotix Inc., Roseville, MN.</offsets></p><fig fig-type="figure" id="F1" orientation="portrait" position="float"><label><offsets xml_i="6662" xml_f="6670" txt_i="2112" txt_f="2120">Figure 1</offsets></label><caption><p><offsets xml_i="6690" xml_f="6867" txt_i="2120" txt_f="2297">Responders to RBX2660 have a greater change in taxa abundance from baseline relative to non-responders at 30 days. Dirichlet-Multinomial parameter pi presented as mean (95% CI).</offsets></p></caption><graphic xlink:href="OFIDIS_ofx163_IF0400"></graphic></fig></sec><sec id="s5"><title><offsets xml_i="6966" xml_f="6977" txt_i="2299" txt_f="2310">Disclosures</offsets></title><p><offsets xml_i="6988" xml_f="6989" txt_i="2311" txt_f="2312">
</offsets><bold><offsets xml_i="6995" xml_f="7004" txt_i="2312" txt_f="2321">S. Khanna</offsets></bold><offsets xml_i="7011" xml_f="7065" txt_i="2321" txt_f="2375">, Rebiotix, Inc.: Scientific Advisor, Consulting fee; </offsets><bold><offsets xml_i="7071" xml_f="7080" txt_i="2375" txt_f="2384">K. Blount</offsets></bold><offsets xml_i="7087" xml_f="7123" txt_i="2384" txt_f="2420">, Rebiotix, Inc.: Employee, Salary; </offsets><bold><offsets xml_i="7129" xml_f="7137" txt_i="2420" txt_f="2428">C. Jones</offsets></bold><offsets xml_i="7144" xml_f="7180" txt_i="2428" txt_f="2464">, Rebiotix, Inc.: Employee, Salary; </offsets><bold><offsets xml_i="7186" xml_f="7196" txt_i="2464" txt_f="2474">B. Shannon</offsets></bold><offsets xml_i="7203" xml_f="7258" txt_i="2474" txt_f="2529">, Rebiotix, Inc.: Research Contractor, Consulting fee; </offsets><bold><offsets xml_i="7264" xml_f="7273" txt_i="2529" txt_f="2538">S. Carter</offsets></bold><offsets xml_i="7280" xml_f="7333" txt_i="2538" txt_f="2591">, Rebiotix, Inc.: Research Contractor, Consulting fee</offsets></p></sec></abstract><counts><page-count count="1"></page-count></counts></article-meta></front></article>